These results suggest that finerenone use may delay CKD progression in T2D patients, which could be attributed to the direct effect of finerenone on the heart and vasculature due to mineralocorticoid receptor activation8,35. The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.